Format

Send to

Choose Destination
Eur J Cancer. 2014 Nov;50(17):2932-8. doi: 10.1016/j.ejca.2014.09.006. Epub 2014 Sep 30.

Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis.

Author information

1
Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Japan. Electronic address: ymatsuo@kuhp.kyoto-u.ac.jp.
2
Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Japan.
3
Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Japan.
4
Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Japan.
5
Department of Radiation Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan.

Abstract

BACKGROUND:

The aim of this study was to perform a survival comparison between stereotactic body radiotherapy (SBRT) and sublobar resection (SLR) in patients with stage I non-small-cell lung cancer (NSCLC) at high risk for lobectomy.

METHODS:

All patients who underwent SBRT or SLR because of medical comorbidities for clinical stage I NSCLC were reviewed retrospectively. Propensity score matching (PSM) was performed to reduce selection bias between SLR and SBRT patients based on age, gender, performance status, tumour diameter, forced expiratory volume in 1 second (FEV1) and Charlson comorbidity index (CCI).

RESULTS:

One hundred and fifteen patients who underwent SBRT and 65 SLR were enrolled. The median potential follow-up periods for SBRT and SLR were 6.7 and 5.3 years, respectively. No treatment-related deaths were observed. Before PSM, the 5-year overall survival (OS) was 40.3% and 60.5% for SBRT and SLR, respectively (P=0.008). PSM identified 53 patients from each treatment group with similar characteristics: a median age of 76 years, a performance status of 0-1, a median tumour diameter of ∼20 mm, a median FEV1 of ∼1.8L and a median CCI of 1. The difference in OS became insignificant between the matched pairs (40.4% and 55.6% at 5 years with SBRT and SLR; P=0.124). The cumulative incidence of cause-specific death was comparable between groups (35.3% and 30.3% at 5 years, P=0.427).

CONCLUSION:

SBRT can be an alternative treatment option to SLR for patients who cannot tolerate lobectomy because of medical comorbidities.

KEYWORDS:

Minimally invasive surgery; Non-small cell lung cancer; Propensity score; Stereotactic body radiotherapy; Treatment outcome

PMID:
25281527
DOI:
10.1016/j.ejca.2014.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center